<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341730</url>
  </required_header>
  <id_info>
    <org_study_id>CUKCVC</org_study_id>
    <nct_id>NCT01341730</nct_id>
  </id_info>
  <brief_title>The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)</brief_title>
  <acronym>PIONEER</acronym>
  <official_title>Evaluation of the Effect of Atorvastatin and Pioglitazone in Carotid Atherosclerosis With the Use of 18Fluoride-Fludeoxyglucose(FDG) Positron Emission Tomography-computed Tomography (PET-CT)Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jeil Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective randomized clinical trial and to compare the antiinflammatory
      effect of atorvastatin single therapy and atorvastatin and pioglitazone combination therapy
      in carotid arteries of stable and unstable angina patients by PET/CT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference of FDG uptake of atherosclerotic plaque in carotid artery by PET CT</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference PET CT parameters in 3 months compared to initial evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Change of Maximum Standardized Uptake Value (SUVmax),Mean Standardized Uptake Value (SUVmean)- no unit for this value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference of laboratory data compared to initial evaluation</measure>
    <time_frame>3 months</time_frame>
    <description>Change of high sensitivity C-reactive protein (hsCRP, mg/dl) Change of low density lipoprotein cholesterol(mg/dl) Change of high density lipoprotein cholesterol(mg/dl) Change of triglyceride (mg/dl) Change of matrix metalloproteinase 9 (mcg/ml) Change of plasminogen activator inhibitor (PAI)-1 (ng/ml) Change of Homeostatic Model Assessment (HOMA) index (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical incidents</measure>
    <time_frame>3 months</time_frame>
    <description>Major adverse cerebro-cardiovascular event: a composite of cardiac death, nonfatal myocardial infarction, stroke, and target vessel revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg&quot; group is to take atorvastatin 20 mg and take follow up PET CT in 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20 mg + Pioglitazone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After the subject take PET CT, he or she is randomized to either &quot; Atorvastatin 20 mg&quot; group or &quot; Atorvastatin 20 mg+ Pioglitazone 30 mg&quot;. The &quot; Atorvastatin 20 mg + Pioglitazone 30 mg&quot; group is to take atorvastatin 20 mg + pioglitazone 30 mg and take follow up PET CT in 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20mg</intervention_name>
    <description>20 mg QD for 3 months</description>
    <arm_group_label>Atorvastatin 20 mg</arm_group_label>
    <other_name>Lipitor 20mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 20 mg + Pioglitazone 30 mg</intervention_name>
    <description>atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months</description>
    <arm_group_label>Atorvastatin 20 mg + Pioglitazone 30 mg</arm_group_label>
    <other_name>Lipitor 20mg plus Actos 30mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject who has undergone percutaneous coronary intervention due to coronary
             artery disease ( stable angina or unstable angina)

          -  The subject described above who has atherosclerotic plaque in his/her carotid artery
             by carotid ultrasonography

          -  The subject who or a legal representative agrees to the clinical trial and gives
             written permission to the IRB-approved form.

        Exclusion Criteria:

          -  The subjets who have taken statins or thiazolidinedione with 4 weeks

          -  Marked elevated liver enzyme ( more than 2.5 fold compared to reference range)

          -  Renal insufficiency patients ( serum creatinine more than 2 mg/dl)

          -  Congestive heart failure ( NYHA class 2-4)

          -  Acue myocardial infarction

          -  Unstable angina with ST segment deviation

          -  Pregnancy

          -  The subjects enrolled in another studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kiyuk Chang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Seoul St. Mary's hospital, The Catholic University of Korea, Colege of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular center, Seoul St. Mary's hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <last_update_submitted>November 23, 2012</last_update_submitted>
  <last_update_submitted_qc>November 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Eun Ho Choo</investigator_full_name>
    <investigator_title>Cardiovascular Center, Seoul St. Mary's Hospital,</investigator_title>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Pioglitazone</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>PET CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

